Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Considering an Autologous Stem Cell Transplant?
Considering an Autologous Stem Cell Transplant?
Are you considering an autologous stem cell transplant? Yes. What were your stage and symptoms when you were first diagnosed?
I was diagnosed with MGUS in 2023 and early-stage myeloma in Oct 2025. How old are you? 67 yrs old. How is your health… besides your myeloma, I mean.
I am in good health, besides high blood pressure that’s well managed and hypothyroidism. MM Patient
Dear MM patient-
I will list a few facts about your situation and then make a couple of recommendations for you to consider.
If I understand your situation, you have been diagnosed with early-stage, aka stage 1, multiple myeloma. Your comment implies that you don’t have any bone or kidney involvement and are in good health.
- Stage 1 MM is a much better prognosis than stage 2 or 3, according to the American Cancer Society. According to research, you should respond well to induction therapy.
- If you have not yet begun induction therapy, consider prehabilitation and enhancing your gut microbiome. Both of these therapies have shown that you will respond better to induction with a reduced risk of side effects.
Depending on your response to induction, complete remission, very good partial, partial, etc., your thinking about an autologous stem cell transplant will revolve around how much deeper your response can be with high-dose, aggressive treatment. In other words, are the pros of ASCT worth the cons of possible side effects, a reduced immune function, and a reduced response to possible future CAR-T cell therapy?
If you achieve a deep remission with induction only and continue treatment with low-dose therapies, consider a relatively new therapy for RR/MM patients that I recently read about. See below. I think it’s reasonable to think that your first line and second line of therapy, with diet, and complementary therapies, can keep your MM at bay for what is now considered to be the standard overall survival of 8-10 years. After that, I think that it is probable that conventional oncology will greatly improve on the current state of CAR-T cell therapy. Good luck-
My point in mentioning the study linked below is that it is now reasonable to consider two lines of treatment- induction therapy of DVRd and the therapy discussed below, each amount to 3-year remissions. Conservatively with a healthy, standard-risk, stage 1, MM patient.
Let me know if you have any questions. Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Bispecific antibodies in myeloma: top trial updates from ASH 2025
Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
“Conclusion: We demonstrate the clinically remarkable and statistically significant PFS and OS benefits of Tec-Dara vs SoC triplets in RRMM, with 83.4% of Tec-Dara pts alive and progression-free at 3 yrs.
Infections with Tec-Dara were well managed with established protocols. This highly effective, off-the-shelf, immunotherapy combination represents a new SoC for RRMM as early as first relapse.”
considering an autologous stem cell transplant considering an autologous stem cell transplant